Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis

Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild‐to‐moderate atopic dermatitis

“…The mean change of all three scores was statistically highly significant (P < 0.0001). The improvement in clinical symptoms observed in this study confirmed the findings of the study published in 1998 by Van Leent et al (23) and is in line with the results of pivotal studies with pimecrolimus cream 1% in the short-term treatment of acute AD in infants, children and adults (1-4). Blood microcirculation in the skin decreased from 33.90 AU at start of treatment to 15.55 AU at end of treatment (P < 0.0001), whereby a substantial reduction of blood flow was noted from day 3 onwards.…”

Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild‐to‐moderate atopic dermatitis

“…The mean change of all three scores was statistically highly significant (P < 0.0001). The improvement in clinical symptoms observed in this study confirmed the findings of the study published in 1998 by Van Leent et al (23) and is in line with the results of pivotal studies with pimecrolimus cream 1% in the short-term treatment of acute AD in infants, children and adults (1-4). Blood microcirculation in the skin decreased from 33.90 AU at start of treatment to 15.55 AU at end of treatment (P < 0.0001), whereby a substantial reduction of blood flow was noted from day 3 onwards.…”

Severity strata for Eczema Area and Severity Index (EASI), modifiedEASI, Scoring Atopic Dermatitis (SCORAD), objectiveSCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis

“…Furthermore, the potential severity band for clear skin on mEASI was 0–0·9 and for ADSI 0–1, secondary to the presence of pruritus. While severity strata were not previously established for ADSI, the original study of ADSI used 6 as a cut‐off for moderate disease, which is consistent with the range of moderate disease observed in this study (range 6–8). ADSI was not a preferred outcome measure for AD and its use was not encouraged by the HOME consensus group .…”

Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981

“… 43 , 44 The inhibition of proinflammatory mediators and cytokines by SDZ ASM 981 may account for the pronounced antipruritic effect of the drug both in atopic dermatitis patients and in hypomagnesaemic rats. 26 This mechanism is proposed also for the antipruritic effect of cyclosporin A in atopic dermatitis patients and may also be the case with cyclosporin A in this rat model. 6 , 45…”

Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild‐to‐moderate atopic dermatitis

“…The mean change of all three scores was statistically highly significant (P < 0.0001). The improvement in clinical symptoms observed in this study confirmed the findings of the study published in 1998 by Van Leent et al (23) and is in line with the results of pivotal studies with pimecrolimus cream 1% in the short-term treatment of acute AD in infants, children and adults (1-4). Blood microcirculation in the skin decreased from 33.90 AU at start of treatment to 15.55 AU at end of treatment (P < 0.0001), whereby a substantial reduction of blood flow was noted from day 3 onwards.…”

Severity strata for Eczema Area and Severity Index (EASI), modifiedEASI, Scoring Atopic Dermatitis (SCORAD), objectiveSCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis

“…Furthermore, the potential severity band for clear skin on mEASI was 0–0·9 and for ADSI 0–1, secondary to the presence of pruritus. While severity strata were not previously established for ADSI, the original study of ADSI used 6 as a cut‐off for moderate disease, which is consistent with the range of moderate disease observed in this study (range 6–8). ADSI was not a preferred outcome measure for AD and its use was not encouraged by the HOME consensus group .…”

Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981

“… 43 , 44 The inhibition of proinflammatory mediators and cytokines by SDZ ASM 981 may account for the pronounced antipruritic effect of the drug both in atopic dermatitis patients and in hypomagnesaemic rats. 26 This mechanism is proposed also for the antipruritic effect of cyclosporin A in atopic dermatitis patients and may also be the case with cyclosporin A in this rat model. 6 , 45…”

Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild‐to‐moderate atopic dermatitis

“…The mean change of all three scores was statistically highly significant (P < 0.0001). The improvement in clinical symptoms observed in this study confirmed the findings of the study published in 1998 by Van Leent et al (23) and is in line with the results of pivotal studies with pimecrolimus cream 1% in the short-term treatment of acute AD in infants, children and adults (1-4). Blood microcirculation in the skin decreased from 33.90 AU at start of treatment to 15.55 AU at end of treatment (P < 0.0001), whereby a substantial reduction of blood flow was noted from day 3 onwards.…”

Severity strata for Eczema Area and Severity Index (EASI), modifiedEASI, Scoring Atopic Dermatitis (SCORAD), objectiveSCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis

“…Furthermore, the potential severity band for clear skin on mEASI was 0–0·9 and for ADSI 0–1, secondary to the presence of pruritus. While severity strata were not previously established for ADSI, the original study of ADSI used 6 as a cut‐off for moderate disease, which is consistent with the range of moderate disease observed in this study (range 6–8). ADSI was not a preferred outcome measure for AD and its use was not encouraged by the HOME consensus group .…”

Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981

“… 43 , 44 The inhibition of proinflammatory mediators and cytokines by SDZ ASM 981 may account for the pronounced antipruritic effect of the drug both in atopic dermatitis patients and in hypomagnesaemic rats. 26 This mechanism is proposed also for the antipruritic effect of cyclosporin A in atopic dermatitis patients and may also be the case with cyclosporin A in this rat model. 6 , 45…”